Genentech: Cary Austin | Senior Pathologist, Pathology

A link to this page has been copied to your clipboard.

http://www.gene.com/scientists/our-scientists/cary-austin

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"At Genentech, we strive to address unmet medical needs through innovative scientific discovery and tireless focus on translating discovery to medicines that help patients in need. I feel fortunate to be contributing to this important effort and to be collaborating with some of the best and brightest minds in science and medicine."

Years at Genentech

Publications

Awards & Honors

I completed a combined MD-PhD program at Albert Einstein College of Medicine in 1998 and an Anatomic Pathology Residency and Autopsy Fellowship at Stanford University Hospital in 2001. During my last year at Stanford, I began a postdoctoral fellowship in the laboratory of Richard H. Scheller and in 2001, moved with the laboratory to Genentech, where I investigated endocytosis and intracellular trafficking of cell surface receptors targeted by cancer therapeutics and armed antibodies. I completed the fellowship in 2005 and joined the Department of Pathology at Genentech, where I have since been providing collaborative pathology support for a variety of pipeline research and development programs and academic-focused projects in basic science, mostly in the areas of Immunology and Infectious Diseases.

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.

Toxicol Sci. 2016 Jul;152(1):72-84.

Rajapaksa KS, Huang T, Sharma N, Lui S, Solon M, Reyes A, Paul S, Yee A, Tao J, Chalasani S, Bien-Ly N, Barck K, Carano RD, Wang J, Rangell L, Bremer M, Danilenko DM, Katavolos P, Hotzel K, Reif K, Austin CD.

View Abstract

As a research pathologist, I use a combination of cutting edge molecular labeling and imaging technologies, in addition to more traditional tissue histology, to formulate and address tissue-based scientific questions contributing to the discovery and evaluation of new therapeutic targets, therapies designed specifically to those targets, and tissue biomarkers developed to predict therapeutic efficacy and/or monitor pharmacodynamic activity of the therapy. I’ve work collaboratively on many project teams over the years ranging from early discovery research through to late stage clinical trials. My focus is on allergic, inflammatory, and infectious diseases, with particular interest in asthma and systemic lupus nephritis.

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

Nature Communications, ISSN: 20411723

Hans Brightbill; Eric Suto; Nicole Blaquiere; Nandhini Ramamoorthi; Swathi Sujatha-Bhaskar; Emily Gogol; Georgette Castanedo; Benjamin T. Jackson; Youngsu Kwon; Susan Haller; Justin Lesch; Karin Bents; Christine Everett; Pawan Bir Kohli; Sandra Linge; Laura Christian; Kathy Barrett; Allan Jaochico; Leo Berezhkovskiy; Peter W. Fan; Zora Modrusan; Kelli Veliz; Michael Townsend; Jason DeVoss; Adam Johnson; Robert Godemann; Wyne Lee; Cary Austin; Brent McKenzie; Jason Hackney; James J. Crawford; Steven Staben; Moulay Hicham Alaoui-Ismaili; Lawren Wu; Nico Ghilardi

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Cary Austin

Senior Pathologist, Pathology

Featured Publication

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.